Cargando…
Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes
Herein, we describe the preparation of liposomes with folate-targeting properties for the encapsulation of anti-sarcosine antibodies (antisarAbs@LIP) and sarcosine (sar@LIP). The competitive inhibitory effects of exogenously added folic acid supported the role of folate targeting in liposome interna...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028781/ https://www.ncbi.nlm.nih.gov/pubmed/27646588 http://dx.doi.org/10.1038/srep33379 |
_version_ | 1782454396483796992 |
---|---|
author | Heger, Zbynek Polanska, Hana Merlos Rodrigo, Miguel Angel Guran, Roman Kulich, Pavel Kopel, Pavel Masarik, Michal Eckschlager, Tomas Stiborova, Marie Kizek, Rene Adam, Vojtech |
author_facet | Heger, Zbynek Polanska, Hana Merlos Rodrigo, Miguel Angel Guran, Roman Kulich, Pavel Kopel, Pavel Masarik, Michal Eckschlager, Tomas Stiborova, Marie Kizek, Rene Adam, Vojtech |
author_sort | Heger, Zbynek |
collection | PubMed |
description | Herein, we describe the preparation of liposomes with folate-targeting properties for the encapsulation of anti-sarcosine antibodies (antisarAbs@LIP) and sarcosine (sar@LIP). The competitive inhibitory effects of exogenously added folic acid supported the role of folate targeting in liposome internalization. We examined the effects of repeated administration on mice PC-3 xenografts. Sar@LIP treatment significantly increased tumor volume and weight compared to controls treated with empty liposomes. Moreover, antisarAbs@LIP administration exhibited a mild antitumor effect. We also identified differences in gene expression patterns post-treatment. Furthermore, Sar@LIP treatment resulted in decreased amounts of tumor zinc ions and total metallothioneins. Examination of the spatial distribution across the tumor sections revealed a sarcosine-related decline of the MT1X isoform within the marginal regions but an elevation after antisarAbs@LIP administration. Our exploratory results demonstrate the importance of sarcosine as an oncometabolite in PCa. Moreover, we have shown that sarcosine can be a potential target for anticancer strategies in management of PCa. |
format | Online Article Text |
id | pubmed-5028781 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50287812016-09-26 Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes Heger, Zbynek Polanska, Hana Merlos Rodrigo, Miguel Angel Guran, Roman Kulich, Pavel Kopel, Pavel Masarik, Michal Eckschlager, Tomas Stiborova, Marie Kizek, Rene Adam, Vojtech Sci Rep Article Herein, we describe the preparation of liposomes with folate-targeting properties for the encapsulation of anti-sarcosine antibodies (antisarAbs@LIP) and sarcosine (sar@LIP). The competitive inhibitory effects of exogenously added folic acid supported the role of folate targeting in liposome internalization. We examined the effects of repeated administration on mice PC-3 xenografts. Sar@LIP treatment significantly increased tumor volume and weight compared to controls treated with empty liposomes. Moreover, antisarAbs@LIP administration exhibited a mild antitumor effect. We also identified differences in gene expression patterns post-treatment. Furthermore, Sar@LIP treatment resulted in decreased amounts of tumor zinc ions and total metallothioneins. Examination of the spatial distribution across the tumor sections revealed a sarcosine-related decline of the MT1X isoform within the marginal regions but an elevation after antisarAbs@LIP administration. Our exploratory results demonstrate the importance of sarcosine as an oncometabolite in PCa. Moreover, we have shown that sarcosine can be a potential target for anticancer strategies in management of PCa. Nature Publishing Group 2016-09-20 /pmc/articles/PMC5028781/ /pubmed/27646588 http://dx.doi.org/10.1038/srep33379 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Heger, Zbynek Polanska, Hana Merlos Rodrigo, Miguel Angel Guran, Roman Kulich, Pavel Kopel, Pavel Masarik, Michal Eckschlager, Tomas Stiborova, Marie Kizek, Rene Adam, Vojtech Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes |
title | Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes |
title_full | Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes |
title_fullStr | Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes |
title_full_unstemmed | Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes |
title_short | Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes |
title_sort | prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028781/ https://www.ncbi.nlm.nih.gov/pubmed/27646588 http://dx.doi.org/10.1038/srep33379 |
work_keys_str_mv | AT hegerzbynek prostatetumorattenuationinthenunumurinemodelduetoantisarcosineantibodiesinfolatetargetedliposomes AT polanskahana prostatetumorattenuationinthenunumurinemodelduetoantisarcosineantibodiesinfolatetargetedliposomes AT merlosrodrigomiguelangel prostatetumorattenuationinthenunumurinemodelduetoantisarcosineantibodiesinfolatetargetedliposomes AT guranroman prostatetumorattenuationinthenunumurinemodelduetoantisarcosineantibodiesinfolatetargetedliposomes AT kulichpavel prostatetumorattenuationinthenunumurinemodelduetoantisarcosineantibodiesinfolatetargetedliposomes AT kopelpavel prostatetumorattenuationinthenunumurinemodelduetoantisarcosineantibodiesinfolatetargetedliposomes AT masarikmichal prostatetumorattenuationinthenunumurinemodelduetoantisarcosineantibodiesinfolatetargetedliposomes AT eckschlagertomas prostatetumorattenuationinthenunumurinemodelduetoantisarcosineantibodiesinfolatetargetedliposomes AT stiborovamarie prostatetumorattenuationinthenunumurinemodelduetoantisarcosineantibodiesinfolatetargetedliposomes AT kizekrene prostatetumorattenuationinthenunumurinemodelduetoantisarcosineantibodiesinfolatetargetedliposomes AT adamvojtech prostatetumorattenuationinthenunumurinemodelduetoantisarcosineantibodiesinfolatetargetedliposomes |